The Oncology Institute, Inc. (NASDAQ:TOI) Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its position in shares of The Oncology Institute, Inc. (NASDAQ:TOI) by 142.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 339,400 shares of the company’s stock after buying an additional 199,300 shares during the period. Renaissance Technologies LLC owned approximately 0.46% of Oncology Institute worth $156,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TOI. Tiff Advisory Services LLC increased its holdings in Oncology Institute by 235.1% in the 2nd quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock valued at $653,000 after purchasing an additional 995,280 shares in the last quarter. FourWorld Capital Management LLC purchased a new stake in shares of Oncology Institute during the 1st quarter valued at about $396,000. Kent Lake Capital LLC lifted its position in Oncology Institute by 9.4% during the 1st quarter. Kent Lake Capital LLC now owns 1,186,713 shares of the company’s stock worth $1,875,000 after acquiring an additional 101,542 shares in the last quarter. Quattro Financial Advisors LLC acquired a new position in Oncology Institute during the 1st quarter worth approximately $88,000. Finally, Nwam LLC purchased a new position in Oncology Institute in the 1st quarter worth approximately $44,000. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Stock Performance

Oncology Institute stock opened at $0.32 on Monday. The company has a debt-to-equity ratio of 3.08, a current ratio of 3.31 and a quick ratio of 2.99. The firm’s fifty day moving average price is $0.35 and its 200 day moving average price is $0.62. The company has a market capitalization of $23.51 million, a price-to-earnings ratio of -0.39 and a beta of 0.60. The Oncology Institute, Inc. has a 12-month low of $0.27 and a 12-month high of $2.66.

Oncology Institute (NASDAQ:TOI) last released its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.07). Oncology Institute had a negative net margin of 18.86% and a negative return on equity of 136.63%. The business had revenue of $98.58 million for the quarter, compared to analysts’ expectations of $103.31 million. During the same quarter last year, the company posted ($0.19) earnings per share.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.